{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:05:24Z","timestamp":1787169924422,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Some previous studies have shown that cerebrospinal fluid (CSF) levels of p-tau231 were significantly higher in patients with Alzheimer's disease (AD) compared to that in patients with mild cognitive impairment (MCI) and normal control (NC), whereas some other studies did not. Due to contradictory results, we aimed to conduct a systematic review and meta-analysis study on previous investigations to examine the potential role of CSF p-tau231 as a biomarker of AD and MCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>PubMed, Scopus, and Web of Science were searched in March 2021 for studies on the CSF level of p-tau231 in AD, MCI, and NC. The statistical analysis was performed via standardized mean difference (SMD) methodology with a 95% confidence interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 10 studies including 1141 subjects were included. The present study showed that CSF level of p-tau231 was significantly higher in AD patients compared to that in MCI patients (SMD = 160.94 [11.11, 310.78],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04) and NC patients (SMD = 436.21 [164.88, 707.54],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00). Moreover, comparison of MCI and NC showed a significantly higher level of CSF p-tau231 in MCI compared to NC (SMD = 341.44 [59.73, 623.14],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>P-tau231 showed to be a valuable biomarker of discrimination AD, MCI, and NC based on our findings. This meta-analysis showed that the CSF p-tau231 can reliably differentiate AD patients from MCI and NC patients. Furthermore, based on our findings the level of CSF p-tau231 was significantly higher in MCI compared to NC. Therefore, p-tau231 can be added to the list of potential biomarkers for the diagnosis of AD and MCI in further studies. However, further investigations are needed to confirm our findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_77_22","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T01:22:32Z","timestamp":1692580952000},"page":"845-851","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["P-tau231 as a Diagnostic Biomarker for Alzheimer's Disease and Mild Cognitive Impairment"],"prefix":"10.4103","volume":"25","author":[{"given":"Fardin","family":"Nabizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Ramezannezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaghayegh","family":"Sadeghmousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20240828","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0025-7125(02)00010-X","article-title":"Dementia epidemiology","volume":"86","author":"Kukull","year":"2002","journal-title":"Med Clin North Am"},{"key":"R2-17-20240828","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1017\/cjn.2016.36","article-title":"The prevalence and incidence of dementia due to Alzheimer's disease:A systematic review and meta-analysis","volume":"43","author":"Fiest","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"R3-17-20240828","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/diagnostics11060984","article-title":"Association between serum concentrations of apolipoprotein A-I (ApoA-I) and Alzheimer's disease:Systematic review and meta-analysis","volume":"11","author":"Zuin","year":"2021","journal-title":"Diagnostics (Basel"},{"key":"R5-17-20240828","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1007\/s12035-019-1500-y","article-title":"Systematic review of miRNA as biomarkers in Alzheimer's disease","volume":"56","author":"Swarbrick","year":"2019","journal-title":"Mol Neurobiol"},{"key":"R6-17-20240828","doi-asserted-by":"crossref","first-page":"607680","DOI":"10.3389\/fneur.2020.607680","article-title":"Similarities and differences in the pattern of Tau hyperphosphorylation in physiological and pathological conditions:Impacts on the elaboration of therapies to prevent Tau pathology","volume":"11","author":"Duquette","year":"2020","journal-title":"Front Neurol"},{"key":"R7-17-20240828","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bcp.12621","article-title":"Emerging drug targets for Ab and tau in Alzheimer's disease:A systematic review","volume":"80","author":"West","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R8-17-20240828","doi-asserted-by":"crossref","first-page":"e12921","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Ab pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol Med"},{"key":"R9-17-20240828","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2174\/1567205014666170203125942","article-title":"Biomarkers for Alzheimer's disease diagnosis","volume":"14","author":"Mantzavinos","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"R10-17-20240828","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1126\/science.1090349","article-title":"Looking backward to move forward:Early detection of neurodegenerative disorders","volume":"302","author":"DeKosky","year":"2003","journal-title":"Science"},{"key":"R11-17-20240828","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework:Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"R13-17-20240828","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0361-9230(03)00087-X","article-title":"Advances in the development of biomarkers for Alzheimer's disease:From CSF total tau and Ab1-42 proteins to phosphorylated tau protein","volume":"61","author":"Hampel","year":"2003","journal-title":"Brain Res Bull"},{"key":"R14-17-20240828","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","article-title":"Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later","volume":"80","author":"Roe","year":"2013","journal-title":"Neurology"},{"key":"R15-17-20240828","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23931","article-title":"Mild cognitive impairment due to Alzheimer disease in the community","volume":"74","author":"Petersen","year":"2013","journal-title":"Ann Neurol"},{"key":"R16-17-20240828","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fnagi.2014.00287","article-title":"Improving CSF biomarkers'performance for predicting progression from mild cognitive impairment to Alzheimer's disease by considering different confounding factors:A meta-analysis","volume":"6","author":"Ferreira","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"R17-17-20240828","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","article-title":"Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer's disease","volume":"11","author":"Barth\u00e9lemy","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"R18-17-20240828","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease:A comparative cerebrospinal fluid study","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"R19-17-20240828","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.59.4.627","article-title":"CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects","volume":"59","author":"Buerger","year":"2002","journal-title":"Neurology"},{"key":"R20-17-20240828","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/cns.12814","article-title":"Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia","volume":"24","author":"Ki\u0111emet-Piska\u010d","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"R21-17-20240828","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses:The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R22-17-20240828","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2:A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"R23-17-20240828","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"R24-17-20240828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neurobiolaging.2004.12.003","article-title":"Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease","volume":"27","author":"Buerger","year":"2006","journal-title":"Neurobiol Aging"},{"key":"R25-17-20240828","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neulet.2005.08.030","article-title":"Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment","volume":"391","author":"Buerger","year":"2005","journal-title":"Neurosci Lett"},{"key":"R26-17-20240828","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3233\/JAD-200056","article-title":"IL-1 beta, IL-6, IL-10, and TNF alpha single nucleotide polymorphisms in human influence the susceptibility to Alzheimer's disease pathology","volume":"75","author":"Leko","year":"2020","journal-title":"J Alzheimer's Dis"},{"key":"R27-17-20240828","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.neurobiolaging.2007.08.010","article-title":"Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment","volume":"30","author":"Brys","year":"2009","journal-title":"Neurobiol Aging"},{"key":"R28-17-20240828","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ana.111","article-title":"Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231","volume":"49","author":"Hampel","year":"2001","journal-title":"Ann Neurol"},{"key":"R29-17-20240828","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3233\/JAD-150705","article-title":"Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment","volume":"50","author":"Leko","year":"2016","journal-title":"J Alzheimer's Dis"},{"key":"R30-17-20240828","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2796.2004.01381.x","article-title":"MRI and CSF studies in the early diagnosis of Alzheimer's disease","volume":"256","author":"De Leon","year":"2004","journal-title":"J Intern Med"},{"key":"R31-17-20240828","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JAD-150167","article-title":"Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease","volume":"49","author":"Spiegel","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"R32-17-20240828","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"R33-17-20240828","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/brain\/awm140","article-title":"No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease","volume":"130","author":"Buerger","year":"2007","journal-title":"Brain"},{"key":"R34-17-20240828","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/archneur.62.5.770","article-title":"Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease","volume":"62","author":"Hampel","year":"2005","journal-title":"Arch Neurol"},{"key":"R35-17-20240828","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","article-title":"Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231","volume":"59","author":"Buerger","year":"2002","journal-title":"Arch Neurol"},{"key":"R36-17-20240828","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000077170","article-title":"Total and phosphorylated tau proteins:Evaluation as core biomarker candidates in frontotemporal dementia","volume":"17","author":"Hampel","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R37-17-20240828","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer's disease:Current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J Intern Med"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_77_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:15:04Z","timestamp":1787166904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_77_22"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_77_22","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}